# Aflibercept and Bevacizumab for Diabetic Maculopathies

> **NCT06850571** · PHASE4 · RECRUITING · sponsor: **Al-Mustansiriyah University** · enrollment: 102 (estimated)

## Conditions studied

- Diabetic Maculopathy

## Interventions

- **DRUG:** Bevacizumab Injection [Avastin]
- **DRUG:** Aflibercept 2Mg/0.05Ml Inj,Oph

## Key facts

- **NCT ID:** NCT06850571
- **Lead sponsor:** Al-Mustansiriyah University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850571, "Aflibercept and Bevacizumab for Diabetic Maculopathies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06850571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*